Lisata Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Lisata Therapeutics, Inc.'s free cash flow has increased -17.46% from $-19.36M last year to $-15.98M, signaling increasing performance

Lisata Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Lisata Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Lisata Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Lisata Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Lisata Therapeutics, Inc.'s profit margin has decreased (381.27%) in the last year from -2.00K% to -9.62K%, signaling decreasing performance

Lisata Therapeutics, Inc.'s short-term assets of $17.70M exceed its short-term liabilities of $3.07M

Lisata Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lisata Therapeutics, Inc.'s return on equity of -101.90%, is lower than 15.00%, indicating bad performance

Lisata Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lisata Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Lisata Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lisata Therapeutics, Inc. has negative free cash flow, indicating cash burn

Lisata Therapeutics, Inc.'s yearly earnings has increased -17.01% since last year from $-19.98M to $-16.59M, signaling increasing performance

Lisata Therapeutics, Inc.'s yearly revenue has decreased -83.00% since last year from $1.00M to $170.00K, signaling decreasing performance

ROIC -157.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lisata Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Lisata Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Lisata Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Lisata Therapeutics, Inc. has insufficient data to evaluate this check.

Lisata Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lisata Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lisata Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lisata Therapeutics, Inc. has insufficient data to evaluate this check.

Lisata Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lisata Therapeutics, Inc. has a price-to-book ratio of 3.13x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Lisata Therapeutics, Inc. has a price-to-sales ratio of 196.30x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue